Hosting partner

This site is intended for UK healthcare professionals

Hosting partner

Prescribing information

Please refer to the Summary of Product Characteristics before prescribing

Tresiba® (insulin degludec) is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year

This sponsored content has been developed, organised, and funded by Novo Nordisk

Welcome to the

Novo Nordisk resource centre for vulnerable people with diabetes

This resource centre aims to provide you with a range of materials discussing the care of vulnerable people with diabetes, including the frail and elderly and those who struggle with mental health issues such as anxiety and depression. Please click on the tabs below to access videos from recently broadcast webcasts, video-based case studies and other downloadable resources. These materials are being provided to raise awareness of the key challenges faced by this population, build healthcare professional confidence in dealing with these issues, ultimately with the aim of changing clinical practice.

We hope that you will find this an interesting and informative resource as you care for vulnerable people living with type 2 diabetes.

Case studies

Find here a number of short video-based case studies covering topics such as diabetes and depression, diabetes distress and diabetes, cognitive function and dementia. Click on the respective video to access content.

Prescribing information

Please refer to the Summary of Product Characteristics before prescribing

Tresiba® (insulin degludec) is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year

This sponsored content has been developed, organised, and funded by Novo Nordisk.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.

UK21TSM00075 | July 2021

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Copyright 2021 Oxbridge Solutions Ltd®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions Ltd® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

This link will take you to a site not operated by the Boehringer Ingelheim and Lilly Diabetes Alliance. The Alliance is not responsible for the content of any linked site.
This link will take you to a site not operated by the Boehringer Ingelheim and Lilly Diabetes Alliance. The Alliance is not responsible for the content of any linked site.

This link is taking you to a page hosted by Lilly.